International childhood Acute Lymphoblastic Leukemia wokshop: Sausalito, CA, 30 November-1 December 2000

Leukemia

Volumn 15, Issue 5, 2001, Pages 707-715

  Pui, C H ^a,b   Sallan, S ^c,d   Relling, M V ^a,e   Masera, G ^f   Evans, W E ^a,e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Neuroscience Institute   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e Nashville Clinical Education Center and Statewide   (United States)

^f SAN GERARDO HOSPITAL   (Italy)

Author keywords

Clinical trials; Glucocorticoids; Minimal residual disease; New agents; Philadelphia chromosome; Risk factors

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAMPTOTHECIN; CD52 ANTIGEN; CISPLATIN; CYTARABINE; CYTOCHROME P450 3A4; DEXAMETHASONE; EPIPODOPHYLLOTOXIN DERIVATIVE; FLUDARABINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; METHYLPREDNISOLONE; OBLIMERSEN; PARACETAMOL; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN P16; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AVASCULAR NECROSIS; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CHROMOSOME 11Q; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESISTANCE; GENETICS; HUMAN; HUMAN CELL; INFECTION; LIVER TOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; WORKSHOP;

EID: 0035001835     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402111     Document Type: Review

References (89)

1. Acute lymphoblastic leukemia
2. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia
3. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
4. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995
5. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995
6. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995
7. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92
8. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991
9. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)
10. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report
11. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation
12. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994
13. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital
14. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995
15. Secondary chromosomal aberrations in 255 childhood cases of Ph-positive acute lymphoblastic leukemia (ALL)
16. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blasts crisis
17. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-ABL positive human leukemia cells to apoptosis due to antileukemic drugs
18. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
19. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
20. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
21. Acute lymphoblastic leukemias with deletion of 11q23 or a novel inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features
22. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation
23. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): A collaborative study of 40 cases
24. Hematologic malignancies with t(4;11)(q21;q23) - A cytogenetic, morphologic, immunopheno-typic and clinical study of 183 cases
25. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
26. Assessment of early response to induction therapy lacks prognostic significance in infant acute lymphoblastic leukemia
27. Marker improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council's 10th AML trial
28. Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set
29. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood
30. Hyperdiploidy of more than 69 chromosomes is strongly associated with the TEL-AML1 fusion and favorable outcome for children with B-lineage ALL
31. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid <45 line
32. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
33. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis
34. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
35. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
36. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood
37. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia
38. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group
39. Potential of lightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia
40. Novel markers of leukemia identified by comparative analysis of gene expression with cDNA arrays
41. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia
42. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
43. New definition of remission in childhood acute lymphoblastic leukemia
44. Risk assessment in ALL: Beyond leukemia cell characteristics
45. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
46. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group
47. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group
48. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
49. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function
50. Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Marked difference between prednisolone and methylpred-nisolone
51. The CYP3A promoters: DNA sequence diversity and concordance of one allele with polymorphic CYP3A5 expression
52. UKALL XI randomised trial stratified CNS treatments and prospective neuropsychological assessment in childhood acute lymphoblastic leukemia (ALL)
53. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone
54. The biology of chronic myeloid leukemia
55. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing MR 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
56. STI571, a molecularly targeted treatment modality for CML
57. Ubiquitin-dependent protein degradation
58. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
59. Proteasome inhibitors: A novel class of potent an effective antitumor agents
60. Proteasome inhibitors as new anti-cancer agents: Biological activity and in vivo detection assay
61. Proteasome inhibition: A new strategy in cancer treatment
62. The proteasome inhibitor PS-341 in cancer therapy
63. Phase I trial of the proteasome inhibitor PS-341 in advanced malignancy
64. Phase I study of PS-34, a novel proteasome inhibitor, in patients with advanced malignancies
65. Preclinical and clinical development of cyclin-dependent kinase modulators
66. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), new G2-checkpoint inhibitor
67. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G(2) arrest
68. In vitro sensitivity of T-cell lymphoblastic leukemia to UNC-01 (7-hydroxystaurosporine) is dependent on p16 protein status: A Pediatric Oncology Group study
69. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans
70. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
71. The Bcl-2 protein family
72. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
73. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C
74. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sersitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other anti-apoptotic proteins
75. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia
76. Cellular expression of antiapoptotic PCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group Study
77. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia
78. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome
79. The CAMPATH-1 antigen (CDw52)
80. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen
81. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells
82. Campath-1H monoclonal antibody therapy
83. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies
84. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
85. Treatment of acute lymphoblastic leukemia (ALL) with CAMPATH-1H: Initial observations
86. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma
87. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: Use of two monoclonal antibodies to prevent grant rejection